VEEV

VEEVA SYSTEMS INC

Healthcare | Large Cap

$1.48

EPS Forecast

$836.4

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-04-30

Vault CRM, High-Impact AI, and a Raised Revenue Forecast: VEEV Delivers in Q2 2027

Veeva Systems Inc. (NYSE: VEEV) released its fiscal 2027 second-quarter results, delivering an earnings per share (EPS) print that reads as a clear win against its own revenue forecast and, for good measure, centered its narrative on AI-driven momentum in Vault CRM. Expect the EPS consensus chatter to follow the trail, as the company aligns quarterly strength with a brighter full-year outlook.

Executive snapshot

Ticker: VEEV (NYSE)

Quarter end: July 31, 2026

Revenue: $928.0 million, up 18% year over year

Subscription revenue: $766.8 million, up 16% year over year

GAAP EPS: $1.66 per share; Non-GAAP EPS: $2.35 per share

Operating income: GAAP $275.0 million; Non-GAAP operating income: $415.9 million

Net income: GAAP $273.4 million; Non-GAAP net income: $387.4 million

Takeaway: The quarter delivered an earnings surprise relative to the company’s own revenue forecast and guidance, with management raising the fiscal 2027 full-year outlook.

Details of the quarter

The results reflect a disciplined growth composition, led by Vault CRM and a strong subscription mix. GAAP operating income climbed 40% year over year to $275.0 million, while non-GAAP operating income rose 18% to $415.9 million. Net income expanded to $273.4 million, a 37% year-over-year gain, with non-GAAP net income up 16% to $387.4 million. Fully diluted GAAP EPS was $1.66, alongside non-GAAP EPS of $2.35.

Veeva underscored that total revenues were $928.0 million for the quarter, with subscription revenues continuing to be the durable growth engine.

Strategic themes: Vault CRM and the AI push

The company framed the quarter around AI-enabled expansion of its industry cloud platform. Vault CRM’s strength was highlighted by more than 180 live customers and notable go-lives, including a handful of top-20 biopharma names and a two-top-20 plus a large enterprise biopharma committing to Vault CRM in the period. The narrative leans into an integrated value proposition: combining domain-specific applications, agent-enabled workflows, data surfaces, and consulting — all aimed at accelerating clinical-to-commercial outcomes.

Veeva’s emphasis on “Agentic CRM” and AI adoption signals a broader strategy: deepen the cloud-native layer for life sciences and push for more efficiency across the go-to-market and clinical operations workflows. The commentary from leadership suggests that the mix of revenue drivers—subscription revenue, in particular—should support sustained margin progression as the company scales.

Outlook: implications for VEEV and sector peers

Management raised its full-year revenue outlook, which in turn supports an optimistic view on the durability of the business, especially in the current AI-inflected software environment for life sciences. The quarterly print demonstrates that the company can translate AI-enabled product investments into tangible top-line and margin improvements, a dynamic peers will watch closely.

For sector peers, several takeaways emerge. First, specialization matters: Vault CRM’s vertical focus appears to deliver outsized returns versus broader cloud playbooks. Second, the integration of AI into go-to-market and clinical workflows isn’t a luxury; it’s a differentiator in the competitive landscape for life sciences cloud software. Finally, the earnings trajectory—robust GAAP and non-GAAP results alongside a raised revenue forecast—sets a high bar for peers aiming to sustain growth with discipline around profitability.

Takeaways and risk considerations

  • EPS trajectory remains solid: GAAP EPS of $1.66 and non-GAAP EPS of $2.35 in the quarter, supported by a healthy margin profile.
  • Revenue momentum is sustainable, anchored by a durable subscription base and the expansion of Vault CRM deployments.
  • The AI narrative is tangible in product adoption, not just rhetoric; the company positions AI as a multiplier for life sciences workflows.
  • Analysts will weigh the updated revenue forecast against evolving competitive dynamics in industry cloud software for life sciences.
  • Investors should monitor the cadence of new customer wins, especially among top-tier biopharma names, as a proxy forsequencing continued growth.

Bottom line: Veeva’s Q2 show underscores a disciplined growth story built on Vault CRM’s industry focus and an AI-accelerated product plan. If the next couple of quarters deliver continued subscription strength and a stable path to higher revenue forecasts, VEEV could increasingly be read as a benchmark for how specialized cloud players translate product excellence into earnings momentum.